Mechanism of Action of ARNI (Angiotensin Receptor–Neprilysin Inhibitor)
Introduction ARNI (Angiotensin Receptor–Neprilysin Inhibitor) represents a major advancement in the treatment of heart failure with reduced ejection fraction (HFrEF). The most widely used ARNI is the fixed-dose combination Sacubitril/Valsartan, marketed as Entresto. Mechanism of Action of ARNI involves dual inhibition of the renin–angiotensin–aldosterone system (RAAS) and the neprilysin (neutral endopeptidase) pathway. This unique mechanism … Read more